Company intelligence / Profile preview
Cabaletta Bio
Philadelphia, Pennsylvania, United Statesorpha.net ↗
- Ownership
- Public · CABA
- Development stage
- Phase 1
01
Overview
Cabaletta Bio has demonstrated favorable safety and promising early efficacy in its RESET™ program with rese-cel (formerly CABA‑201), a CD19-CAR T cell therapy. Early data show that a single weight-based dose can provide transformative responses in autoimmune diseases after discontinuation of immunosuppressants, with most patients experiencing minimal or no cytokine release syndrome or neurotoxicity. The company continues to expand enrollment across multiple indications and geographies, with registrational trial discussions ongoing for myositis[4][5][6].
- Therapeutic areas
- ImmunologyNeurologyRheumatology
- Modalities
- Engineered T cell therapiesCAR-T cells (CD19-CAR T)CAART (Chimeric AutoAntibody Receptor T cells)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $533.2M
- Total revenue
- $0
- Enterprise value
- $333.8M
Beyond the preview
Go deeper on Cabaletta Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cabaletta Bio.